Aquestive Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−4.08%
vs ±12.4% implied · ×0.33
shaded = implied · ▲▼ = realized
Aquestive Therapeutics has 0 disclosed suppliers and 13 disclosed customers in SEC filings.
Aquestive Therapeutics, Inc.
3.92
—
SentenceIndivior accounted for approximately 73% and 62% of our revenues for 2025 and 2024, respectively, and we believe in the future will continue to account for a substantial part of our revenues.
basisAQST FY2025 revenue $45MINDV FY2025 revenue $1.2B
SentenceAquestive is the exclusive sole manufacturer and supplier of Sympazan for Assertio and will receive manufacturing fees from Assertio for the product through the expiration of such License Agreement.
AQST 10-Kaccession 0001398733-26-000018
SentenceOn October 26, 2022, we entered into a License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc., pursuant to which we granted an exclusive, worldwide license of its intellectual property for Sympazan to Assertio during the term of that agreement for an upfront payment of $9,000.
AQST 10-Kaccession 0001398733-26-000018
SentenceWe licensed commercial rights for this product to Hypera in Brazil (which Hypera markets as Ondif).
AQST 10-Kaccession 0001398733-26-000018
SentenceWe manufacture based on receipt of purchase orders from our licensees, and our licensees have an obligation to accept these orders once quality assurance validates the quality of the manufactured product with agreed upon technical specifications.
AQST 10-Kaccession 0001398733-26-000018
SentenceOn November 3, 2020, we entered into the Monetization Agreement with Marathon.
AQST 10-Kaccession 0001398733-26-000018
SentenceUnder the terms of the MTPA license agreement, Aquestive was the exclusive manufacturer and supplier of Exservan for MTPA in the United States.
AQST 10-Kaccession 0001398733-26-000018
SentenceWe entered into the Pharmanovia Agreement with Pharmanovia, effective as of September 26, 2022, pursuant to which we granted Pharmanovia an exclusive license to certain of our intellectual property to develop and commercialize Libervant for the treatment of prolonged or acute, convulsive seizures in all ages in certain countries of the Territory, as defined in the Pharmanovia Agreement, during the term of the Pharmanovia Agreement.
AQST 10-Kaccession 0001398733-26-000018
SentenceOn August 13, 2025, we entered into a purchase and sale agreement with funds managed by RTW Investments LP ("RTW" or "Purchaser").
AQST 10-Kaccession 0001398733-26-000018
SentenceUnder the terms of the Monetization Agreement, we sold to Marathon all of our contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion's apomorphine product, KYNMOBI, an apomorphine film therapy for the treatment of off episodes in Parkinson's disease patients, which received approval from the FDA on May 21, 2020.
AQST 10-Kaccession 0001398733-26-000018
SentenceWe licensed our intellectual property to Cynapsus Therapeutics, Inc., a company that was acquired by Sunovion for the commercialization of KYNMOBI under the Sunovion License Agreement.
AQST 10-Kaccession 0001398733-26-000018
SentenceDuring the second quarter of 2025, Aquestive earned a $500 milestone payment in connection with the sale of Emylif pursuant to the terms of the license agreement with Zambon.
AQST 10-Kaccession 0001398733-26-000018
SentencePursuant to the terms of the March 2012 agreement with Zevra, we began to receive milestone and royalty revenues for Azstarys.
AQST 10-Kaccession 0001398733-26-000018
Expected move
Inputsspot 3.89exp Nov 20ATM strike 4ATM straddle 0.53IV 69%